Journal of Crohn's & colitis · 2026
A descriptive comparison of phase 3 results and head-to-head trials in inflammatory bowel diseases.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chkolnaia Zlata, Peyrin-Biroulet Laurent, Uzzan Mathieu
Аннотация
BACKGROUND: With the increasing number of effective therapies for inflammatory bowel diseases (IBD), determining optimal treatment sequences is challenging. Given the impracticality of conducting randomized head-to-head trials for every comparison, this study assessed whether phase 3 placebo-controlled trials can reliably predict outcomes of published head-to-head studies.
METHODS: Three randomized head-to-head trials without placebo arms were analyzed alongside their corresponding phase 3 placebo-controlled trials. Effect sizes for clinical and endoscopic endpoints were extracted for comparison.
RESULTS: In the VARSITY trial, vedolizumab achieved an 8.8% higher clinical remission rate than adalimumab at week 52 in patients with ulcerative colitis. Placebo-controlled studies estimated a 17.3% advantage for vedolizumab; however, differences in trial design and patient populations between GEMINI-1 and ULTRA-2 limited the robustness of this indirect comparison. In Crohn's disease, indirect comparisons of IM-UNITI, CLASSIC-II, and CHARM suggested an 11.6%-18.6% higher efficacy for adalimumab compared with ustekinumab in biologic-naïve patients, yet the SEAVUE head-to-head trial found no significant difference at week 52. Most recently, the SEQUENCE trial demonstrated a +15.6% superiority of risankizumab over ustekinumab in endoscopic remission at week 48 among bio-exposed Crohn's disease patients, whereas indirect comparisons between FORTIFY and IM-UNITI were confounded by clinically relevant population differences.
CONCLUSION: Significant heterogeneity in trial design, populations, and outcome reporting limits the predictive value of placebo-controlled trials. Randomized head-to-head trials remain essential for optimizing IBD therapeutic strategies.
METHODS: Three randomized head-to-head trials without placebo arms were analyzed alongside their corresponding phase 3 placebo-controlled trials. Effect sizes for clinical and endoscopic endpoints were extracted for comparison.
RESULTS: In the VARSITY trial, vedolizumab achieved an 8.8% higher clinical remission rate than adalimumab at week 52 in patients with ulcerative colitis. Placebo-controlled studies estimated a 17.3% advantage for vedolizumab; however, differences in trial design and patient populations between GEMINI-1 and ULTRA-2 limited the robustness of this indirect comparison. In Crohn's disease, indirect comparisons of IM-UNITI, CLASSIC-II, and CHARM suggested an 11.6%-18.6% higher efficacy for adalimumab compared with ustekinumab in biologic-naïve patients, yet the SEAVUE head-to-head trial found no significant difference at week 52. Most recently, the SEQUENCE trial demonstrated a +15.6% superiority of risankizumab over ustekinumab in endoscopic remission at week 48 among bio-exposed Crohn's disease patients, whereas indirect comparisons between FORTIFY and IM-UNITI were confounded by clinically relevant population differences.
CONCLUSION: Significant heterogeneity in trial design, populations, and outcome reporting limits the predictive value of placebo-controlled trials. Randomized head-to-head trials remain essential for optimizing IBD therapeutic strategies.